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ABSTRACT
P/CAF is a histone acetyltransferase enzyme which
was originally identi®ed as a CBP/p300-binding
protein. In this manuscript we report that human
P/CAF is acetylated in vivo. We ®nd that P/CAF is
acetylated by itself and by p300 but not by CBP.
P/CAF acetylation can be an intra- or intermolecular
event. The intermolecular acetylation requires the
N-terminal domain of P/CAF. The intramolecular
acetylation targets ®ve lysines (416±442) at the
P/CAF C-terminus, which are in the nuclear localisa-
tion signal (NLS). Finally, we show that acetylation
of P/CAF leads to an increment of its histone acetyl-
transferase (HAT) activity. These ®ndings identify a
new post-translation modi®cation on P/CAF which
may regulate its function.
INTRODUCTION
The packaging of the eukaryotic genome into chromatin
provides the means for compaction of the entire genome inside
the nucleus, restricting the access of many regulatory proteins
required for essential biological processes such as replication,
transcription, DNA repair and recombination (1). To counter-
balance this repressive nature of chromatin, several factors are
able to destabilise the nucleosome to facilitate the interaction
of proteins with the DNA. Recent studies have identi®ed two
types of protein complexes capable of altering chromatin
structure. One of them utilises the energy coming from the
ATP hydrolysis to alter the structure of nucleosomes (2).
The second one includes complexes which modify covalently
the histone tails (3,4), by acetylation, methylation,
phosphorylation, etc.
It has been known for many years that acetylation of the
N-terminal tails of histones correlates with transcription
activation (5,6). However, the underlying mechanisms and
biological signi®cance are just beginning to be revealed thanks
to the identi®cation of the ®rst nuclear histone acetyltrans-
ferase (HAT), GCN5. Subsequently, many other transcription
coactivators have been shown to be capable of acetylating
nucleosomal histones: CBP/p300 (7), P/CAF (8), ACTR/SRC
(9) TAFII250 (10), etc.
P/CAF was originally identi®ed as a CBP/p300-binding
protein due to its sequence similarity to the yeast GCN5
(yGCN5) (8). P/CAF and GCN5 show sequence conservation
in the regions responsible for the HAT activity and the binding
to yADA2 co-factor (11,12). In vitro, yGCN5 ef®ciently
acetylates free histones in solution, but does not recognise
nucleosomal histones as a substrate (13). However, in vivo,
yGCN5 is found in a large complex containing yADA2 and
yADA3 (14). In this complex, yGCN5 is the HAT enzymatic
component and is responsible for the acetylation of nucleo-
somal histones (15). In contrast, P/CAF has an intrinsic ability
to acetylate nucleosomal histones in vitro.
PCAF is also found in a complex consisting of more than 20
distinct polypeptides (16). Some of them are identical to
TBP-associated factors (TAFs) and others are histone fold-
containing factors. P/CAF is capable of activating transcrip-
tion through interaction with CBP (17), and independently
from CBP but depending on P/CAF's intrinsic HAT activity
(18). P/CAF is essential for myogenesis (19) and is capable of
acetylating and coactivating MyoD transcription factor.
P/CAF and GCN5 are very unstable enzymes that rapidly
and irreversibly lose histone acetyltransferase activity. In vitro,
P/CAF is stabilised by the continuous presence of acetyl CoA
and autoacetylation (20). Here, we demonstrate that P/CAF is
autoacetylated in vivo and is a target for p300 acetylation, but
not for CBP. We also ®nd that the P/CAF acetylation can
occur in cis and in trans. Finally, we show that acetylation of
P/CAF leads to an increment of its HAT activity.
MATERIALS AND METHODS
Cell culture and transfections
U2Os and C2C12 cells were maintained in Dulbecco's
modi®ed Eagle's medium (DMEM) with 10% fetal calf
serum (FCS) and grown at 37°C, 5% CO2. Cells were
transfected by standard calcium phosphate coprecipitation
with 10 mg of either expression vector. Transfected cells were
washed after 14 h and harvested 36 h after transfection.
Finally, they were washed once in phosphate-buffered saline
(PBS). C2C12 differentiation to myotubes was induced by
changing the 10% FCS by 5% horse serum for 4±10 days.
Plasmids and recombinant proteins
PGEX-P/CAF (FL: full length), pGEX-P/CAF (352±832),
pGEX-P/CAF (352±658) and pGEX-P/CAF (352±658 muta-
ted in the HAT domain) have been described elsewhere (18).
Mutations in the P/CAF cDNA (pGEX-P/CAF amino acids
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352±658) were introduced at lysines 416, 428, 430, 441, 442
or different combinations of them, using the QuikChange
mutagenesis kit (Stratagene) following the manufacturer's
instructions and veri®ed by DNA sequencing. GST and GST
fusion proteins were expressed in Escherichia coli XA90
using the pGEX (Pharmacia) vector system, for 4 h after
0.1 mM IPTG addition at 30°C. Puri®cation from crude
bacterial lysates was performed as in Bannister and
Kouzarides (7). The pCX-P/CAF-Flag (FL) was a gift from
J. Sinclair. pCX-P/CAFDHAT-Flag: the pCX-P/CAF-Flag
plasmid was digested with BbrpI PvuII. An 84 bp fragment
was released and the plasmid religated. This cloning strategy
recovers the P/CAF frame leaving a deletion of 28 amino acids
in the HAT domain. PCX-GFP-PCAF(FL)-Flag: GFP was
inserted in-frame as a SmaI fragment into pCX-P/CAF(FL)-
Flag SmaI site. PCX-GFP-PCAFDHAT-Flag: GFP was
inserted in-frame as a SmaI fragment into pCX-P/CAF(FL)-
Flag SmaI site. PCX-GFP-P/CAF(K-R)-Flag: the 527 bp BlgII
PvuII fragment of P/CAF(FL) was replaced by that containing
the K-R mutations. PCX-GFP-P/CAF(K-R/DHAT)-Flag:
pCX-GFP-P/CAF(K-R)-Flag plasmid was digested with
BbrpI PvuII and religated. PGEX-HDAC1, pCDNA3-
HDAC1-Flag and pCDNA3-p300-HA have been described
elsewhere (7,18,21).
Cell extract preparation
Total cell extracts were prepared in RIPA (50 mM Tris, pH 7.5,
150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS, 1 mM EDTA) buffer by keeping the cells on ice for
20 min followed by centrifugation at 13 000 r.p.m. for 10 min
at 4°C. All buffers contained protease inhibitors (Boehringer).
HAT and immunoprecipitation (IP) HAT assay
The in vitro acetylation assay IP-HAT assays were performed
as described elsewhere (7). Basically, extracts from trans-
fected U2OS cells were made using 500 ml of RIPA buffer.
The lysis mixture was incubated on ice for 20 min and
cleared by centrifugation at 12 000 g for 10 min at 4°C.
Two micrograms of HA antibody was used to precipitate for
3 h at 4°C with rotation. Then 15 ml of protein A/protein
G-Sepharose beads (a 50:50 mix) were added and incubated
overnight at 4°C with rotation. The immune complexes were
pelleted by gentle centrifugation and washed three times with
1 ml of RIPA. After the ®nal wash, the buffer was aspirated
down to 30 ml and the liquid HAT assay was done as described
(7). Puri®ed chicken erythrocyte histones (Sigma) were used
as substrate.
In vitro translation and pull-down assay
In vitro translations and GST pull-downs were performed
essentially as described previously (18). The buffer used for
the pull-downs was a variation of Z¢ (25 mM HEPES pH 7.5,
12.5 mM MgCl2, 20% glycerol, 0.1% NP40, 250 mM KCl).
Immunoprecipitations and western analysis
Immunoprecipitations and western analysis were performed as
described elsewhere (22), with modi®cations; 10-cm dishes of
U2Os were transfected with 10 mg of each expression vector
and harvested 36 h post-transfection. Cells were lysed in 1 ml
of RIPA lysis buffer, and debris were removed by centrifuga-
tion. The cleared lysate was subjected to immunoprecipitation
with 2 mg of the antibody for 3 h at 4°C with rotation. Then
15 ml of protein A/protein G-Sepharose beads (a 50:50 mix)
was added and incubated overnight at 4°C with rotation. The
immune complexes were pelleted by gentle centrifugation and
washed three times with 1 ml of RIPA buffer and resuspended
in loading buffer for SDS±PAGE. All buffers contained
protease inhibitors (Boehringer). Western blotting was per-
formed using standard procedures and visualised using an
ECL kit (Amersham). The antibodies used were whole
antisera anti-acetyl-Lys ab193 (abcam) at 1:1000 dilution,
whole antisera anti P/CAF at 1:500 dilution, af®nity puri®ed
anti-Flag M2 (Kodak) at 1:1100 dilution and af®nity puri®ed
anti HA (Santa Cruz) at 1:1000 dilution.
RESULTS
P/CAF is acetylated in vivo
Previous work by Herrera et al. (20) has shown that P/CAF is
autoacetylated in vitro. However, it is not yet known whether
P/CAF acetylation occurs in vivo. To investigate this possi-
bility, we have used an antibody raised against chemically
acetylated histone H4, which recognises many acetylated
proteins such as E2F, CBP, etc. (23) (anti-acetyl-Lys; ab-193
from abcam). First, we tested the antibody speci®city for
P/CAF acetylation. To that end, FL recombinant GST-P/CAF
was incubated with acetyl-CoA and the acetylation status of
GST-P/CAF was analysed by western blotting using the
antibody anti-acetyl-Lys. The result (Fig. 1A) demonstrates
that the antibody recognises speci®cally acetylated P/CAF
in vitro, in an incubation-time dependent manner. The bottom
band in the gel (indicated with a small arrow) corresponds to a
GST-P/CAF degradation product.
We then wanted to establish whether P/CAF is also
acetylated in vivo. To that end, U2OS cells were transfected
with P/CAF-Flag, P/CAF-Flag mutated in the HAT domain
(P/CAFDHAT-Flag) which has lost the ability to acetylate
histones (data not shown), and HDAC1-Flag as a control for
the Flag epitope. Flag proteins were immunoprecipitated using
the anti-Flag antibody and their acetylation level was deter-
mined by western blotting using the anti-acetyl-Lys antibody.
We found (Fig. 1B, bottom part) that P/CAF-Flag is clearly
recognised by the anti-acetyl-Lys antibody. Neither P/CAF
mutated in the HAT domain (P/CAFDHAT-Flag) nor
HDAC1-Flag were recognised by the anti-acetyl-Lys anti-
body. This suggests that P/CAF is acetylated in vivo. To
con®rm this hypothesis, we analysed the acetylation status of
the endogenous P/CAF from C2C12 cells. To do that, we
immunoprecipitated P/CAF from C2C12 cells using a speci®c
anti-P/CAF antibody and tested its acetylation level by
western blotting, using the anti-acetyl-Lys antibody. The
results in Figure 1C indicate that endogenous P/CAF is also
acetylated in vivo.
P/CAF N-terminal domain is required for P/CAF trans
acetylation in vivo
Having established that P/CAF is acetylated in vivo, we sought
to investigate whether P/CAF is acetylated by an intra-
molecular (cis) or intermolecular (trans) event. To do so, we
should be able to follow P/CAF (HAT-active protein) and
P/CAFDHAT (HAT-inactive protein) after co-transfection.
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Since both proteins co-migrate in an SDS±PAGE gel, we
made a fusion of GFP to P/CAF-Flag to get GFP-P/CAF-Flag,
which can be easily distinguished from P/CAF-Flag in an
SDS±PAGE gel and maintains HAT activity (data not shown).
Then, we transfected U2OS cells with combinations of
vectors expressing active (GFP-P/CAF-Flag) and inactive
(P/CAFDHAT-Flag) proteins; immunoprecipitated them by
using the anti-Flag antibody, and ®nally analysed their
expression level and acetylation status by western blotting
using the anti-Flag and anti-acetyl-Lys antibodies, respect-
ively. The results in Figure 2A (bottom panel, lane 2) show
that inactive P/CAF (P/CAFDHAT-Flag) is acetylated in the
presence of active P/CAF (GFP-P/CAF-Flag). Both proteins
were expressed in U2OS to similar levels (top panel). The
Figure 2. P/CAF is acetylated in cis and in trans in vivo. (A) P/CAF is
acetylated in trans. U2Os cells were transfected with 10 mg of pCX-GFP-P/
CAF-Flag and pCX-P/CAFDHAT-Flag plasmids. Whole cell extracts from
transfected cells were prepared and Flag-proteins from them were immuno-
precipitated using an anti-Flag antibody. The immunocomplexes were tested
for P/CAF acetylation status by western blotting, using the anti-acetyl-Lys
antibody (bottom part of the ®gure) and an antibody against the Flag tag
(top part). Positions of the acetylated GFP-P/CAF-Flag and acetylated
P/CAFDHAT-Flag are indicated by arrows. (B) P/CAF N-terminal domain
is required for P/CAF trans acetylation in vivo. U2OS cells were transfected
with 10 mg of pCX-P/CAF(FL)-Flag and pCX-P/CAFDHAT (352±832)-Flag
plasmids. Whole cell extracts were prepared, Flag proteins were immuno-
precipitated by using the Flag antibody and P/CAF acetylation was analysed
by western blotting using the anti-acetyl-Lys antibody (bottom part) and the
anti-Flag antibody as a control (top part). The small arrow indicates where
acetylated P/CAFDHAT (352±832)-Flag should be found. (C) Deletion of
the N-terminal domain does not affect P/CAF-P/CAF interaction. GST,
GST-P/CAF and GST-P/CAF (352±832) fusion proteins were expressed and
the binding to P/CAF FL in vitro translated and radiolabelled was deter-
mined by an in vitro pull down experiment (see Materials and Methods).
Input represents 25% of total P/CAF input. The arrow indicates the P/CAF
position in the gel.
Figure 1. P/CAF is an acetyl-protein in vivo. (A) The antibody against
Acetyl-Lys recognises acetylated P/CAF; 0.5 mg of recombinant GST-P/
CAF was incubated for 0±2 h with acetyl-CoA, and the acetylated products
were analysed by western blotting using an antibody that recognises acetyl-
ated lysines (anti-acetyl-Lys). The bottom band in the gel (indicated by a
small arrow) corresponds to a GST-P/CAF degradation product. (B) P/CAF
is acetylated in vivo. U2Os cells were transfected with 10 mg of Pcx-P/CAF-
Flag, Pcx-P/CAFDHAT-Flag and pCDNA3-HDAC1-Flag plasmids. Whole
cell extracts from transfected cells were prepared, and Flag-proteins from
them were immunoprecipitated using an anti-Flag antibody. The immuno-
complexes were tested for P/CAF acetylation status by western blotting,
using the antibody, which recognises acetylated lysines (anti-acetyl-
Lys) (bottom part), and an antibody against the Flag-tag (top part).
(C) Endogenous P/CAF is acetylated in vivo. P/CAF from C2C12 cells was
immunoprecipitated using an anti P/CAF antibody or the preimmune serum
(as a control), and the immunocomplexes were analysed for their acetylation
level by western blotting, using the anti-acetyl-Lys antibody.
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weak acetylation band of P/CAFDHAT-Flag that we detect
in the absence of GFP-P/CAF-Flag (bottom panel, lane 1)
could be due to the activity of endogenous P/CAF
enzyme. The results in Figure 2A suggest that acetylation of
P/CAF(FL) can occur in vivo by an intermolecular reaction (in
trans) in vivo.
Then we tried to identify the P/CAF region that is acetylated
in trans. To that end, U2OS cells were transfected with P/CAF
(FL)-Flag and P/CAFDHAT (352±832)-Flag (which lacks the
®rst 352 amino acids) expression vectors. Flag proteins were
immunoprecipitated using the anti-Flag antibody and their
expression level and acetylation status were determined by
western blotting using the anti-Flag antibody (Fig. 2B, top
panel) and anti-acetyl-Lys antibody (Fig. 2B, bottom panel),
respectively. The result con®rms our previous ®ndings,
showing that P/CAF FL is acetylated in vivo (lanes 2 and 3),
and also indicates that P/CAFDHAT (352±832)-Flag cannot
be acetylated by P/CAF(FL)-Flag (lane 3, arrow). The lack of
acetylation of P/CAFDHAT (352±832)-Flag could be due to
the deletion of the P/CAF-P/CAF interaction domain and not
the acetylation sites per se. To rule out that possibility, we
analysed the P/CAF-P/CAF interaction by in vitro pull down
experiments. More precisely, radiolabelled P/CAF was pulled
down with GST-P/CAF(FL) and GST-P/CAFDHAT (352±
832) and the bound protein was detected by radiography.
Figure 2C shows that P/CAF is capable of interacting weakly
with itself in vitro and this interaction is not affected when the
N-terminal domain is deleted. We conclude that deletion of
the N-terminal domain abrogates the P/CAF acetylation in
trans in vivo.
P/CAF is acetylated in cis at its C-terminal domain
Once established that the P/CAF N-terminal domain is the
major acetylation site in trans in vivo, we sought to determine
whether P/CAF could also be acetylated in cis, as an
intramolecular event. To ensure that we were monitoring a
trans-independent event, we have used recombinant GST-P/
CAF (352±832) (which cannot be acetylated in trans by
P/CAF(FL) in vivo, Fig. 2B) and GST-P/CAFDHAT (352±
832) in an in vitro acetylation assay. Both recombinant
proteins were incubated with 14C-acetyl-CoA, in presence or
absence of GST-P/CAF(FL), and their acetylation levels were
analysed by ¯uorography. Figure 3A shows that GST-P/CAF
(352±832) is autoacetylated in vitro (lanes 4 and 5) while
con®rming that P/CAF(FL) cannot acetylate P/CAFDHAT
(352±832) (lane 3). We conclude from this experiment that
P/CAF can be acetylated in cis, by an intramolecular event at
the C-terminal domain.
The bands of autoacetylated GST-P/CAF(FL) are weaker
than autoacetylated GST-P/CAF (352±832); this is probably
due to the fact that GST-P/CAF (352±832) has a higher
intrinsic HAT activity than GST-P/CAF(FL) in vitro, as
shown in Figure 3B, and as described previously (18).
Once it was established that P/CAF (352±832) is acetylated
in vitro as an intramolecular event, we sought to determine
Figure 3. P/CAF is acetylated in cis at the C-terminus. (A) Recombinant GST-P/CAF(FL), GST-P/CAF (352±832) and GST-P/CAFDHAT (352±832) were
expressed in E.coli and puri®ed. Fusion proteins were used in an in vitro acetylation assay. Acetylated proteins were visualised by ¯uorography. (B) HAT
assay of GST-P/CAF(FL) and GST-P/CAF (352±832) recombinant proteins. (C) U2Os cells were transfected with 10 mg of pCX-P/CAF (352±832)-Flag and
pCX-P/CAFDHAT (352±832)-Flag plasmids. Whole cell extracts were prepared, Flag proteins were immunoprecipitated by using the Flag antibody and the
immunocomplexes were tested for P/CAF acetylation status by western blotting, using the antibody which recognises acetylated lysines (anti-acetyl-Lys)
(bottom part) and an antibody against the Flag-tag (top part). The position of the inactive protein is indicated by an arrow.
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whether it is also acetylated in vivo. To do that, we transfected
U2OS cells with P/CAF (352±832)-Flag and P/CAFDHAT
(352±832)-Flag expression vectors. The Flag proteins were
immunoprecipitated using the anti-Flag antibody and analysed
by western blotting, using the anti-acetyl-Lys and anti-Flag
antibodies. Figure 3C, shows that P/CAF (352±832)-Flag is
acetylated (lane 1) in vivo. This autoacetylation is likely to
occur as an intramolecular event because P/CAF lacking the
N-terminal domain (1±352) cannot be acetylated in trans,
either in vivo (Fig. 2B) or in vitro (Fig. 3A), by P/CAF(FL).
We conclude that P/CAF can be autoacetylated in vivo, both
in trans and in cis at the C-terminal domain (amino acids 352±
832).
P/CAF is acetylated by p300 in vivo
P/CAF was originally identi®ed as a p300/CBP-interacting
protein (8). CBP and p300 have HAT activity and are able to
acetylate other factors different from histones (p53, GATA, 1,
ELKF1, E2F1, TCF, HMGi(Y), MyoD, TFIIE, F, etc.) (24±
31). Therefore, we sought to determine whether either CBP or
p300 could acetylate P/CAF in vivo. To that end, we
transfected P/CAF-Flag and P/CAFDHAT-Flag in the pres-
ence or absence of p300-HA. Flag proteins were puri®ed by
immunoprecipitation using the anti-Flag antibody (Fig. 4A,
lanes 2, 3, 5 and 6) and their acetylation levels were
determined by western blotting, using the anti-acetyl-Lys
antibody. The amount of p300-HA expressed in each
transfection was monitored by IP with anti-HA antibody
(lanes 1, 4 and 7). Our results show that p300 is able to
acetylate P/CAF in vivo (lane 5). The weak acetylation band of
P/CAFDHAT-Flag that we detect in absence of P/CAF-Flag
(lane 6) could be due to the HAT activity of endogenous p300
or P/CAF enzymes.
We did not detect any increase in acetylation by p300 over
the autoacetylation levels on active P/CAF (lanes 2 and 3).
The reasons may be that acetylation by p300 could be masked
by the strong autoacetylation signal due to P/CAF itself or that
acetylation sites in P/CAF are redundant.
We also wanted to determine whether CBP could acetylate
P/CAF. To do that, P/CAFDHAT-Flag and CBP-HA plasmids
were transfected into U2OS cells, Flag proteins were puri®ed
by immunoprecipitation using the anti-Flag antibody (Fig. 4B,
lanes 2 and 3) and their acetylation levels were determined by
western blotting using the anti-acetyl-Lys antibody. The
expression levels of P300-HA and CBP-HA in each transfec-
tion were monitored by IP with anti-HA antibody (lanes 1 and
4). Figure 4B shows that p300 (lane 2) but not CBP (lane 3) is
capable of acetylating P/CAF in vivo. The presence of HA tag
on CBP is not affecting its HAT activity, because when we
analysed HAT activity of HA-CBP and HA-p300 by IP-HAT
assay, both proteins showed similar HAT activity on histones
(Fig. 4C).
Figure 4. P/CAF is acetylated by p300 in vivo. (A) PCX-P/CAF-Flag, PCX-
P/CAFDHAT-Flag and pCDNA3-p300-HA plasmids were transfected into
U2OS cells. Proteins were immunoprecipitated using antibodies against HA
(lanes 1, 4 and 7) and Flag (lanes 2, 3, 5 and 6) tags. The acetylation level
of P/CAF was analysed by western blotting using the anti-acetyl-Lys
antibody (bottom panel). (B) PCX-P/CAFDHAT-Flag, pCDNA3-p300-HA
and pCDNA3-CBP-HA plasmids were transfected into U2OS cells. The
proteins were immunoprecipitated using antibodies against HA and Flag
tags and the acetylated status of P/CAF was analysed by western blotting
using the anti-acetyl-Lys antibody. (C) IP-HAT assay. U2OS cells were
transfected with pCDNA3-p300-HA, pCDNA3-CBP-HA or the empty
vector. CBP and p300 were immunoprecipitated using antibodies against
HA and the HAT activity associated with the immunocomplexes was
determined by liquid HAT assay.
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P/CAF is autoacetylated in its nuclear localisation signal
(NLS)
To try to establish the function of P/CAF autoacetylation, we
decided to identify the lysines on P/CAF, which are acetylated
in cis. To this end, we expressed various domains of P/CAF as
GST-fusion proteins and tested their autoacetylation by an
in vitro acetylation assay. Figure 5A clearly shows that GST-
P/CAF (352±658) (which contains the HAT domain) is
autoacetylated in vitro. The GST fusion [GST-P/CAF (489±
658)], which does not include the region between 352 and 489
(but still maintains HAT activity, data not shown) lost the
ability to be acetylated (Fig. 5A, lane 2). To analyse this
region (amino acids 352±489) more closely, we mutated the
lysines (Ks) present between positions 352 and 658 in the
GST-P/CAF (352±658) construct (Fig. 5B) and analysed
the autoacetylation activities of these mutants in an in vitro
assay (Fig. 5C). (All the mutants were active in a HAT activity
assay, data not shown.) The mutant that has lost the ®ve Ks
(416, 428, 430, 441 and 442) is not autoacetylated in vitro
(Fig. 5C, lane 3). After examination of the 352±444 region, we
realised that this region contains a putative NLS consensus
sequence, between amino acids 425 and 445 (Fig. 5B).
Therefore, we wanted to investigate whether P/CAF contains a
functional NLS between these amino acids and whether
P/CAF autoacetylation in cis could affect the NLS function.
To investigate these possibilities, we constructed a GFP-P/
CAF-Flag in which the ®ve lysines at the putative NLS (428,
430, 441 and 442) were mutated to arginines (which maintain
the positive charge of the NLS) [GFP-PCAF (Ks-Rs)]. C2C12
cells were transfected with GFP-P/CAF and GFP-PCAF(Ks-
Rs) and we determined their cellular localisation by ¯uores-
cence. The results in Figure 6 show that GFP-P/CAF is nuclear
before C2C12 differentiation (myoblast) and after differenti-
ation to myotubes (top panels), and that the lysines between
425 and 445 are essential for localising the protein in the
nucleus (bottom panels) de®ning the unique nuclear localis-
ation signal within P/CAF between 425 and 445 amino acids.
On the other hand, the acetylation of the NLS on P/CAF
opened the possibility of regulating intracellular localisation
by acetylation. However, GFP-P/CAF shows exclusively
intranuclear localisation on different cell types (293-T,
U2OS, C2C12; Fig. 6 and data not shown) and does not
change localisation upon differentiation (Fig. 6), high
con¯uence or growth in minimal medium (data not shown).
P/CAF autoacetylation and HAT activity
It has been proposed that P/CAF autoacetylation could play a
role in regulating its HAT enzymatic activity (20). So we
sought to determine whether autoacetylation in cis could
affect the acetyltransferase activity. To do that, we incubated
®rst either GST-P/CAF (352±658) or GST-P/CAF (352±658)
mutated at lysines 416, 428, 430, 441 and 442 (P/CAF non-
acetylable mutant) in the presence and in the absence of cold
acetyl-CoA and then P/CAF HAT activity on identical
amounts of histone H3 was analysed in an in vitro acetylation
assay by ¯uorography (see diagram in Fig. 7A). The results in
Figure 7A and their quanti®cation in Figure 7B show that after
incubation with acetyl-CoA, P/CAF is more active to acetylate
histone H3. This effect is probably due to two independent
processes: ®rst, P/CAF stabilisation by acetyl-CoA as has been
previously described by Herrera et al. (20), which probably
affects to the same extent P/CAF and the non-acetylable
P/CAF mutant; and secondly, P/CAF intra-acetylation, which
increases 2- to 3-fold P/CAF HAT activity on histone H3.
DISCUSSION
The results presented here show that P/CAF is an acetyl-
protein in vivo. P/CAF is acetylated by itself and by p300, but
not by CBP in vivo. Acetylation of P/CAF seems to increase
P/CAF stability/histone acetyltransferase activity.
In this paper, we give some evidence for the implementation
of an acetylation cascade: P/CAF is acetylated in vivo by itself
and by another HAT, p300, suggesting that an acetylase
modi®es the activity of a second acetylase, probably in order
to transmit a biological signal. The fact that the bromodomain,
Figure 5. Mapping of P/CAF cis-acetylation sites. (A) Recombinant
GST-P/CAF(352±658) (lane 1), GST-P/CAF(489±658) (lane 2), GST-P/
CAFDHAT(352±658) (lane 3) and GST (lane 4) were tested for autoacetyl-
ation in an in vitro acetylation assay. The acetylated proteins were visual-
ised by ¯uorography. (B) Schematic representation of the P/CAF (352±658)
region (acetylated lysines are indicated). (C) Fluorograph showing P/CAF
acetylation of the GST-P/CAF (352±658) wt (lane 2) and punctual mutants
(lanes 3±9) indicated on the top of the ®gure. Lane 1 corresponds to the
protein molecular weight marker.
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which is present in many chromatin-working proteins, recog-
nises acetyl-lysines (32±36) also suggests a cascade mechan-
ism mediated by acetylation. How is the acetylation signal
transmitted? We have shown that incubation of P/CAF with
acetyl-CoA increases P/CAF HAT activity on histone H3,
suggesting that acetylation could be a mechanism to regulate
P/CAF HAT activity. On the other hand, our work demon-
strates that P/CAF can be acetylated at the N-terminal domain
in trans and at the C-terminus by an intramolecular event. This
acetylation at different sites could have different in vivo
consequences. It is possible that P/CAF is recruited to
different promoters by distinct sets of transcription factors
and P/CAF acetylation could contribute to this speci®city.
P/CAF acetylation could be involved in this recruitment by
affecting the P/CAF-transcription factor interaction. In fact,
HAT-transcription factor interactions have been shown to be
regulated by acetylation (31), although we have not detected
any difference in binding to CBP2, E1A, E2F and p53 in vitro
(data not shown). Another possibility is that acetylation may
change P/CAF speci®city to acetylate different histones or
factors. This may lead to differential activated states necessary
for some promoters but not others. We have not observed any
change in the P/CAF speci®city to acetylate, in vitro, different
histones upon autoacetylation (data not shown); however, the
pool of P/CAF autoacetylated represents very little of the total
amount of enzyme in the reaction so any small change could
be masked. Even in this unfavourable condition what we could
observe is an increase in the global HAT activity of P/CAF on
histone H3.
In summary, we have identi®ed a new post-translational
modi®cation of P/CAF in vivo, which leads to an increment of
its HAT activity and could be part of a signal transduction
cascade leading to regulation of the cellular HAT activities.
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Figure 6. The acetylated lysines in cis are essential for the P/CAF NLS function. C2C12 cells were transfected with pCX-GFP-P/CAF(FL) and pCX-GFP-P/
CAF(FL)(Ks-Rs) in which lysines 428, 430, 441 and 442 have been mutated to arginines. Localisation of the expressed proteins was detected before and after
differentiation of C2C12 cells by ¯uorescence.
Figure 7. P/CAF auto-acetylation and HAT activity. (A) GST-P/CAF (352±
658) or the non-acetylable P/CAF mutant [GST-P/CAF (352±658)K-R
mutated at 416, 428, 430, 441 and 442 lysines] were incubated in the pres-
ence or absence of acetyl-CoA for 5 min, then puri®ed H3 was added to the
reaction and the P/CAF HAT activity on H3 was analysed by ¯uorography.
(B) The results in (A) were quanti®ed using a Molecular Dynamics machine
and normalised relative to the values obtained in absence of acetyl-CoA
(value 1).
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